Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial
Racura Oncology starts Harness-1 Phase 1 with first patient dosed for RC220 + osimertinib in EGFR-mutant NSCLC; early safety data awaited.
Latest Stories — SECTOR DESK
Inoviq Announces Rapid Tumour-Killing Activity in Study of CAR-Exosomes on Ovarian Cancer Cells
Inoviq CAR-exosomes show rapid in vitro ovarian cancer killing, ~90% in OVCAR-3/Caov-3 within 48 hours, eyeing first-in-human trials by 2028.
Avecho Biotechnology Advances Phase III Insomnia Trial to Full Enrolment Size
Avecho Biotechnology Phase III insomnia trial moves to full enrolment after DMB recommendation; no serious adverse events in first 244 participants.
CONNEQT Health Lodges FDA Pre-Submission for SphygmoCor Cloud in Push toward Software Model
CONNEQT Health lodges FDA Pre-Submission for SphygmoCor Cloud, its cloud SaMD pivot with 510(k) target in FY27; could unlock subscription/licensing revenue.
Recce Pharmaceuticals Advances Diabetic Foot Infection Trial to Pivotal Phase 3
Recce Pharmaceuticals expands diabetic foot infection trial to Phase 3, broadening recruitment and adding below-knee ulcers; dual Australia-Indonesia program.
Adherium: Scaling Digital Respiratory Care and Assessing the US Payer Opportunity
Adherium pivots to US RPM subscriptions, pursuing Value-Based Care contracts as iCARE validates cost savings; targets 10k shipments and 40k patients in FY2026.
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Actinogen Gets Third DMC Green Light for XanaMIA as November Topline Nears
Actinogen's XanaMIA gets third DMC green light; trial proceeds unchanged as November 2026 topline readout nears, easing near-term interruption risk.
Dimerix Engages Everest Medicines to Commercialise DMX-200 Kidney Disease Treatment across Asia
Dimerix inks exclusive DMX-200 FSGS deal with Everest in Asia; upfront $14.1m, potential milestones up to ~$466m and 15% royalties.
EVE Health Group Initiates Pilot Study of Libbo Oral Soluble Film to Treat ED
EVE Health launches pilot Libbo ED study (oral soluble film), a key bioequivalence step toward regulatory approval; results expected by end-September. ASX:EVE
Five New Stocks For The Healthcare Sector Rotation: PME, TLX, TNE, 360, and SDR
ASX healthcare rotation heats up as PME, TLX, TNE, 360, SDR emerge—five stocks positioned to ride the sector shift amid oil, inflation and volatility.
Vitrafy Life Sciences Raising $30m to Scale Guardion Production and US Expansion
Vitrafy Life Sciences raises $30m to scale Guardion production and accelerate US expansion amid US blood market demand.